Hans Ericsson
Research Subjects
Research Interests
Hans Ericsson has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
Maria Heijer
Integrated Bioanalysis Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca Gothenburg Sweden
13 shared publicationsEva‐Lotte Lindstedt
Projects, Research and Early Development, Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden
5 shared publications- Joanna Parkinson
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden
5 shared publications Karin Nelander
Biometrics CVRM, Late CVRM BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden
5 shared publicationsJudith Hartleib‐Geschwindner
Late‐Stage Clinical Development Cardiovascular Renal and Metabolism AstraZeneca BioPharmaceuticals R&D Gothenburg Sweden
4 shared publicationsMagnus Kjaer
Early Biometrics and Statistical Innovation Data Science and AI BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden
4 shared publications
Latest Publications
- 9 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3322-3330
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial
Myeloperoxidase (MPO)-derived oxidants reduce nitric oxide bioavailability and promote coronary microvascular dysfunction, cardiomyocyte stiffening and interstitial fibrosis—mechanisms implicated in the pathogenesis of heart failure with preserved and mildly reduced ejection fraction. Here, in a multicenter, randomized, double-blind, placebo-controlled, three-arm, parallel-group phase 2b trial of patients with heart failure and an ejection fraction of >40%, we evaluated whether treatment with the MPO inhibitor mitiperstat versus placebo for 48 weeks improved symptoms and exercise function at 16 weeks (the co-primary endpoints were the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and 6-minute walk distance (6MWD)). Secondary endpoints included changes in natriuretic peptides and inflammatory markers (up to 48 weeks) and echocardiographic parameters (up to 24 weeks). In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS (placebo-corrected difference in mean change from baseline, –1.4 points (95% confidence interval (CI) –3.9, 1.2; P = 0.29), 6MWD (3.8 m (95% CI –3.1, 10.8)); P = 0.28) or any secondary endpoint. Adverse and serious adverse events, including infections, were similar among groups except for maculopapular rash (mitiperstat, 3.6%; placebo, 0.4%). These results indicate that mitiperstat was safe and well tolerated but did not improve symptoms or exercise function in chronic heart failure with preserved or mildly reduced ejection fraction. ClinicalTrials.gov registration: NCT04986202.
- 9 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3322-3330
Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial
Myeloperoxidase (MPO)-derived oxidants reduce nitric oxide bioavailability and promote coronary microvascular dysfunction, cardiomyocyte stiffening and interstitial fibrosis—mechanisms implicated in the pathogenesis of heart failure with preserved and mildly reduced ejection fraction. Here, in a multicenter, randomized, double-blind, placebo-controlled, three-arm, parallel-group phase 2b trial of patients with heart failure and an ejection fraction of >40%, we evaluated whether treatment with the MPO inhibitor mitiperstat versus placebo for 48 weeks improved symptoms and exercise function at 16 weeks (the co-primary endpoints were the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and 6-minute walk distance (6MWD)). Secondary endpoints included changes in natriuretic peptides and inflammatory markers (up to 48 weeks) and echocardiographic parameters (up to 24 weeks). In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS (placebo-corrected difference in mean change from baseline, –1.4 points (95% confidence interval (CI) –3.9, 1.2; P = 0.29), 6MWD (3.8 m (95% CI –3.1, 10.8)); P = 0.28) or any secondary endpoint. Adverse and serious adverse events, including infections, were similar among groups except for maculopapular rash (mitiperstat, 3.6%; placebo, 0.4%). These results indicate that mitiperstat was safe and well tolerated but did not improve symptoms or exercise function in chronic heart failure with preserved or mildly reduced ejection fraction. ClinicalTrials.gov registration: NCT04986202.
- Open Access
- 3 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9) , e70282
Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P‐gp Inhibitor
Balcinrenone (AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist with a distinct mode of action being developed as a fixed‐dose combination with the sodium–glucose cotransporter‐2 inhibitor dapagliflozin for the treatment of heart failure with impaired kidney function, and chronic kidney disease. In this Phase 1 randomized open‐label three‐way crossover study we investigated the effect of food on balcinrenone/dapagliflozin pharmacokinetics, and the pharmacokinetics of balcinrenone when dosed with a P‐glycoprotein (P‐gp) inhibitor. Fourteen healthy participants were administered an oral capsule of balcinrenone/dapagliflozin 40 mg/10 mg in three dosing periods: fasted (reference), fed (high‐fat, high‐calorie meal) and with a P‐gp inhibitor (quinidine 300 mg × 2). Balcinrenone exposure was comparable in the fed and fasted states (geometric mean ratios [GMRs] [90% CI]: maximum plasma concentration [C max ] 1.05 [0.88, 1.25]; area under the plasma concentration–time curve from time 0 to infinity [AUC inf ] 1.12 [1.06, 1.19]). In the fed state, dapagliflozin AUC inf was comparable to the fasted state (GMR [90% CI] 1.05 [1.01, 1.09]), whereas C max was decreased (GMR [90% CI] 0.59 [0.51, 0.69]), in line with previous dapagliflozin food interaction studies. Co‐administration with quinidine increased balcinrenone exposure: GMRs (90% CI) 1.48 (1.24, 1.76) and 1.24 (1.17, 1.31) for C max and AUC inf , respectively, but AUC fold increase was <2, the level used for classification of sensitive P‐gp substrates. All interventions were well tolerated. In conclusion, this study supports dosing of balcinrenone/dapagliflozin without regard to food. Balcinrenone is not considered a sensitive P‐gp substrate. No P‐gp based dosing precautions are warranted based on this study.
- 3 September 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (9) , e70282
Open AccessEffect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics and the Pharmacokinetics of Balcinrenone When Dosed with a P‐gp Inhibitor
Balcinrenone (AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist with a distinct mode of action being developed as a fixed‐dose combination with the sodium–glucose cotransporter‐2 inhibitor dapagliflozin for the treatment of heart failure with impaired kidney function, and chronic kidney disease. In this Phase 1 randomized open‐label three‐way crossover study we investigated the effect of food on balcinrenone/dapagliflozin pharmacokinetics, and the pharmacokinetics of balcinrenone when dosed with a P‐glycoprotein (P‐gp) inhibitor. Fourteen healthy participants were administered an oral capsule of balcinrenone/dapagliflozin 40 mg/10 mg in three dosing periods: fasted (reference), fed (high‐fat, high‐calorie meal) and with a P‐gp inhibitor (quinidine 300 mg × 2). Balcinrenone exposure was comparable in the fed and fasted states (geometric mean ratios [GMRs] [90% CI]: maximum plasma concentration [C max ] 1.05 [0.88, 1.25]; area under the plasma concentration–time curve from time 0 to infinity [AUC inf ] 1.12 [1.06, 1.19]). In the fed state, dapagliflozin AUC inf was comparable to the fasted state (GMR [90% CI] 1.05 [1.01, 1.09]), whereas C max was decreased (GMR [90% CI] 0.59 [0.51, 0.69]), in line with previous dapagliflozin food interaction studies. Co‐administration with quinidine increased balcinrenone exposure: GMRs (90% CI) 1.48 (1.24, 1.76) and 1.24 (1.17, 1.31) for C max and AUC inf , respectively, but AUC fold increase was <2, the level used for classification of sensitive P‐gp substrates. All interventions were well tolerated. In conclusion, this study supports dosing of balcinrenone/dapagliflozin without regard to food. Balcinrenone is not considered a sensitive P‐gp substrate. No P‐gp based dosing precautions are warranted based on this study.
- Open Access
- 3 July 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (10) , 3656-3665
The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone
Aim: Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment versus participants with normal hepatic function. Methods: Participants with mild and moderate hepatic impairment (Child–Pugh Class A [ n = 8] and Child–Pugh Class B [ n = 8]) were compared with group matched controls with normal hepatic function [ n = 9]. Eligible participants received a single oral dose of 50‐mg balcinrenone. Blood and urine samples were collected. Safety and tolerability were monitored. Results: In participants with mild hepatic impairment, balcinrenone exposure (area under the plasma concentration–time curve [AUC] and maximum plasma concentration [ C max ]) was similar compared with participants with normal hepatic function. In participants with moderate hepatic impairment, C max was similar, but there was a slight and statistically significant 30% (90% CI 4%–61%) increase in AUC compared with participants with normal hepatic function. Balcinrenone was well tolerated. All reported adverse events were of mild to moderate intensity. Conclusions: Compared with participants with normal hepatic function, balcinrenone exposure was similar in participants with mild hepatic impairment. AUC, but not C max , was slightly increased in participants with moderate hepatic impairment. We do not consider the minor AUC increase seen in participants with moderate hepatic impairment to be clinically relevant. Thus, we would not recommend any dose adjustment for patients with mild or moderate hepatic impairment.
- 3 July 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (10) , 3656-3665
Open AccessThe effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone
Aim: Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment versus participants with normal hepatic function. Methods: Participants with mild and moderate hepatic impairment (Child–Pugh Class A [ n = 8] and Child–Pugh Class B [ n = 8]) were compared with group matched controls with normal hepatic function [ n = 9]. Eligible participants received a single oral dose of 50‐mg balcinrenone. Blood and urine samples were collected. Safety and tolerability were monitored. Results: In participants with mild hepatic impairment, balcinrenone exposure (area under the plasma concentration–time curve [AUC] and maximum plasma concentration [ C max ]) was similar compared with participants with normal hepatic function. In participants with moderate hepatic impairment, C max was similar, but there was a slight and statistically significant 30% (90% CI 4%–61%) increase in AUC compared with participants with normal hepatic function. Balcinrenone was well tolerated. All reported adverse events were of mild to moderate intensity. Conclusions: Compared with participants with normal hepatic function, balcinrenone exposure was similar in participants with mild hepatic impairment. AUC, but not C max , was slightly increased in participants with moderate hepatic impairment. We do not consider the minor AUC increase seen in participants with moderate hepatic impairment to be clinically relevant. Thus, we would not recommend any dose adjustment for patients with mild or moderate hepatic impairment.
- Open Access
- 8 May 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70259
Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat
Mitiperstat is a novel myeloperoxidase inhibitor being investigated for the treatment of heart failure, metabolic dysfunction‐associated steatohepatitis, and chronic obstructive pulmonary disease. Pharmacokinetic data from five clinical trials were used to develop a mitiperstat population pharmacokinetics (popPK) model. In total, 2856 plasma samples from 128 mitiperstat‐treated participants were collected during the first‐in‐human single‐ascending dose (SAD) study; multiple‐ascending dose studies (MAD) in healthy volunteers, including healthy Japanese and Chinese volunteers (JCMAD); the phase 2a SATELLITE study in patients with heart failure with preserved/mildly reduced ejection fraction (HFpEF/HFmrEF); and from a study in patients with severe renal impairment. The mitiperstat concentration‐time data were pooled and analyzed with the software NONMEM. The covariates considered in this analysis were baseline estimated glomerular filtration rate (eGFR), baseline body weight, baseline body mass index, sex, race (Asian or non‐Asian), age, disease status (healthy volunteers or patients with HFpEF/HFmrEF), and formulation (oral suspension or tablet). The final popPK model is a two‐compartment model with first‐order absorption and linear elimination. Baseline body weight, disease status, Asian race, and eGFR were identified as significant covariates for apparent clearance, and age was identified as a significant covariate for apparent central volume of distribution. The final model predicts that severe renal impairment and lower body weight have the largest impact on exposure. Exposure to mitiperstat increased as eGFR declined. This popPK model constitutes an important step toward optimizing doses for efficacy and safety in the different mitiperstat development programs. Trial Registration: ClinicalTrials.gov : NCT02712372
- 8 May 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70259
Open AccessPopulation Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat
Mitiperstat is a novel myeloperoxidase inhibitor being investigated for the treatment of heart failure, metabolic dysfunction‐associated steatohepatitis, and chronic obstructive pulmonary disease. Pharmacokinetic data from five clinical trials were used to develop a mitiperstat population pharmacokinetics (popPK) model. In total, 2856 plasma samples from 128 mitiperstat‐treated participants were collected during the first‐in‐human single‐ascending dose (SAD) study; multiple‐ascending dose studies (MAD) in healthy volunteers, including healthy Japanese and Chinese volunteers (JCMAD); the phase 2a SATELLITE study in patients with heart failure with preserved/mildly reduced ejection fraction (HFpEF/HFmrEF); and from a study in patients with severe renal impairment. The mitiperstat concentration‐time data were pooled and analyzed with the software NONMEM. The covariates considered in this analysis were baseline estimated glomerular filtration rate (eGFR), baseline body weight, baseline body mass index, sex, race (Asian or non‐Asian), age, disease status (healthy volunteers or patients with HFpEF/HFmrEF), and formulation (oral suspension or tablet). The final popPK model is a two‐compartment model with first‐order absorption and linear elimination. Baseline body weight, disease status, Asian race, and eGFR were identified as significant covariates for apparent clearance, and age was identified as a significant covariate for apparent central volume of distribution. The final model predicts that severe renal impairment and lower body weight have the largest impact on exposure. Exposure to mitiperstat increased as eGFR declined. This popPK model constitutes an important step toward optimizing doses for efficacy and safety in the different mitiperstat development programs. Trial Registration: ClinicalTrials.gov : NCT02712372
- Open Access
- 17 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (7) , 1937-1946
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone
Aims: The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs . those with normal renal function. Methods: Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m 2 ) not on dialysis were compared with group‐matched control participants with eGFR ≥ 90 mL/min/1.73 m 2 . Eligible participants received a single oral dose of 150 mg balcinrenone, and blood and urine samples were collected for analysis. Results: The total apparent balcinrenone clearance was 50% lower in the severe renal impairment group, resulting in an approximately two‐fold higher area under the curve (AUC) and a 1.4‐fold higher maximum observed plasma concentration in the severe renal impairment group compared with the control group. The terminal half‐life and plasma protein binding were similar in both groups. Balcinrenone was safe and well tolerated in all participants. All reported adverse events were of mild‐to‐moderate severity and not considered related to balcinrenone. Conclusions: Balcinrenone exposure was approximately two‐fold higher in participants with severe renal impairment compared with the group‐matched control participants. Based on linear regression analysis of total apparent balcinrenone clearance vs . baseline eGFR, the AUC exposure is predicted to be 2 compared with those with an eGFR of 60 mL/min/1.73 m 2 . In light of these findings, no dose adjustment based on eGFR is needed in two ongoing studies that target these patients (MIRO‐CKD [NCT06350123] and BalanceD‐HF [NCT06307652]).
- 17 February 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (7) , 1937-1946
Open AccessThe effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone
Aims: The aim of this phase 1 trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment vs . those with normal renal function. Methods: Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m 2 ) not on dialysis were compared with group‐matched control participants with eGFR ≥ 90 mL/min/1.73 m 2 . Eligible participants received a single oral dose of 150 mg balcinrenone, and blood and urine samples were collected for analysis. Results: The total apparent balcinrenone clearance was 50% lower in the severe renal impairment group, resulting in an approximately two‐fold higher area under the curve (AUC) and a 1.4‐fold higher maximum observed plasma concentration in the severe renal impairment group compared with the control group. The terminal half‐life and plasma protein binding were similar in both groups. Balcinrenone was safe and well tolerated in all participants. All reported adverse events were of mild‐to‐moderate severity and not considered related to balcinrenone. Conclusions: Balcinrenone exposure was approximately two‐fold higher in participants with severe renal impairment compared with the group‐matched control participants. Based on linear regression analysis of total apparent balcinrenone clearance vs . baseline eGFR, the AUC exposure is predicted to be 2 compared with those with an eGFR of 60 mL/min/1.73 m 2 . In light of these findings, no dose adjustment based on eGFR is needed in two ongoing studies that target these patients (MIRO‐CKD [NCT06350123] and BalanceD‐HF [NCT06307652]).
- Open Access
- 7 December 2024
- Published by Wiley
The effect of severe renal impairment on the pharmacokinetics, safety, and tolerability of balcinrenone
Aims: The aim of this phase 1 trial was to assess the pharmacokinetics, safety, and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment versus those with normal renal function. Methods: Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) not on dialysis were compared with group-matched control participants with eGFR ≥90 mL/min/1.73 m2. Eligible participants received a single oral dose of 150 mg balcinrenone, and blood and urine samples were collected for analysis. Results: The total apparent balcinrenone clearance was 50% lower in the severe renal impairment group, resulting in a ~two-fold higher area under the curve (AUC) and a 1.4-fold higher maximum observed plasma concentration in the severe renal impairment group versus the control group. The terminal half-life and plasma protein binding were similar in both groups. Balcinrenone was safe and well tolerated in all participants. All adverse events reported were of mild-to-moderate severity and not considered related to balcinrenone. Conclusions: Balcinrenone exposure was approximately two-fold higher in participants with severe renal impairment compared with the group-matched control participants. Based on obtained results, the AUC exposure is predicted to be <50% higher in patients with an eGFR of 20 mL/min/1.73 m2 compared with those with an eGFR of 60 mL/min/1.73 m2. In light of these findings, no dose adjustment based on eGFR is needed in two ongoing studies that target these patients (MIRO-CKD [NCT06350123] and BalanceD-HF [NCT06307652]).
- 7 December 2024
- Published by Wiley
Open AccessThe effect of severe renal impairment on the pharmacokinetics, safety, and tolerability of balcinrenone
Aims: The aim of this phase 1 trial was to assess the pharmacokinetics, safety, and tolerability of balcinrenone (previously AZD9977) in participants with severe renal impairment versus those with normal renal function. Methods: Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2) not on dialysis were compared with group-matched control participants with eGFR ≥90 mL/min/1.73 m2. Eligible participants received a single oral dose of 150 mg balcinrenone, and blood and urine samples were collected for analysis. Results: The total apparent balcinrenone clearance was 50% lower in the severe renal impairment group, resulting in a ~two-fold higher area under the curve (AUC) and a 1.4-fold higher maximum observed plasma concentration in the severe renal impairment group versus the control group. The terminal half-life and plasma protein binding were similar in both groups. Balcinrenone was safe and well tolerated in all participants. All adverse events reported were of mild-to-moderate severity and not considered related to balcinrenone. Conclusions: Balcinrenone exposure was approximately two-fold higher in participants with severe renal impairment compared with the group-matched control participants. Based on obtained results, the AUC exposure is predicted to be <50% higher in patients with an eGFR of 20 mL/min/1.73 m2 compared with those with an eGFR of 60 mL/min/1.73 m2. In light of these findings, no dose adjustment based on eGFR is needed in two ongoing studies that target these patients (MIRO-CKD [NCT06350123] and BalanceD-HF [NCT06307652]).
- Open Access
- 14 October 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (5) , e70029
Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants
In this study, the mass balance, pharmacokinetics (PK) and metabolism of atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor, were investigated in healthy male subjects. A single oral dose of 200 mg [14C]atuliflapon suspension was administered to six healthy male subjects. Mass balance, PK and metabolite profiles of atuliflapon were analyzed using radioactivity monitoring and liquid chromatography with mass spectrometry analysis. The safety of atuliflapon was assessed during the study. Atuliflapon was rapidly absorbed with a median tmax of 1.5 h, followed by a biphasic decline in plasma exposure rendering a terminal half‐life of ~20 h. Unchanged atuliflapon was the predominant radioactive component in plasma, accounting for 40.1% of the total drug‐related exposure (DRE), while a direct N‐glucuronide was the only metabolite exceeding 10% of DRE, accounting for 20.9%. Renal excretion of intact atuliflapon accounted for 14C]atuliflapon suspension was well tolerated in healthy male subjects. The human metabolism and disposition data obtained will support future development and submissions of atuliflapon as a potential candidate drug for the treatment of cardiovascular, cardiorenal, and respiratory indications.
- 14 October 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (5) , e70029
Open AccessDisposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants
In this study, the mass balance, pharmacokinetics (PK) and metabolism of atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor, were investigated in healthy male subjects. A single oral dose of 200 mg [14C]atuliflapon suspension was administered to six healthy male subjects. Mass balance, PK and metabolite profiles of atuliflapon were analyzed using radioactivity monitoring and liquid chromatography with mass spectrometry analysis. The safety of atuliflapon was assessed during the study. Atuliflapon was rapidly absorbed with a median tmax of 1.5 h, followed by a biphasic decline in plasma exposure rendering a terminal half‐life of ~20 h. Unchanged atuliflapon was the predominant radioactive component in plasma, accounting for 40.1% of the total drug‐related exposure (DRE), while a direct N‐glucuronide was the only metabolite exceeding 10% of DRE, accounting for 20.9%. Renal excretion of intact atuliflapon accounted for 14C]atuliflapon suspension was well tolerated in healthy male subjects. The human metabolism and disposition data obtained will support future development and submissions of atuliflapon as a potential candidate drug for the treatment of cardiovascular, cardiorenal, and respiratory indications.
- Open Access
- 12 August 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (12) , 3212-3220
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
Aims: Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio‐metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics. This study assessed mitiperstat pharmacokinetics, safety and tolerability in participants with severe renal impairment and normal renal function, to inform inclusion of participants with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 in phase 3.Methods: Participants with severe renal impairment (eGFR ≥15 and 2) who were not on dialysis (n = 10) and group‐matched controls (eGFR ≥90 mL/min/1.73 m2; n = 10) received a single mitiperstat 2.5 mg oral tablet. Blood samples were collected at intervals for 2 weeks and urine samples for 24 h post‐dose.Results: Total apparent mitiperstat clearance was 10.83 L/h in the severe renal impairment cohort and 25.62 L/h in the control cohort. The area under the plasma concentration–time curve was 2.37‐fold higher (90% confidence interval [CI]: 1.79, 3.12) in the severe renal impairment cohort than in the control cohort, with longer elimination half‐life and similar maximum concentration. Non‐renal clearance was similar between the cohorts.Conclusions: Mitiperstat apparent clearance was approximately twofold lower in individuals with severe renal impairment than in those with normal renal function. Lower clearance was driven by reduced renal clearance; non‐renal clearance was similar. Mitiperstat was generally well tolerated by participants with severe renal impairment and normal renal function. These findings, together with efficacy and safety/tolerability data from phase 2b, will guide the dosing regimen for phase 3.
- 12 August 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (12) , 3212-3220
Open AccessThe effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
Aims: Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio‐metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics. This study assessed mitiperstat pharmacokinetics, safety and tolerability in participants with severe renal impairment and normal renal function, to inform inclusion of participants with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 in phase 3.Methods: Participants with severe renal impairment (eGFR ≥15 and 2) who were not on dialysis (n = 10) and group‐matched controls (eGFR ≥90 mL/min/1.73 m2; n = 10) received a single mitiperstat 2.5 mg oral tablet. Blood samples were collected at intervals for 2 weeks and urine samples for 24 h post‐dose.Results: Total apparent mitiperstat clearance was 10.83 L/h in the severe renal impairment cohort and 25.62 L/h in the control cohort. The area under the plasma concentration–time curve was 2.37‐fold higher (90% confidence interval [CI]: 1.79, 3.12) in the severe renal impairment cohort than in the control cohort, with longer elimination half‐life and similar maximum concentration. Non‐renal clearance was similar between the cohorts.Conclusions: Mitiperstat apparent clearance was approximately twofold lower in individuals with severe renal impairment than in those with normal renal function. Lower clearance was driven by reduced renal clearance; non‐renal clearance was similar. Mitiperstat was generally well tolerated by participants with severe renal impairment and normal renal function. These findings, together with efficacy and safety/tolerability data from phase 2b, will guide the dosing regimen for phase 3.
- Open Access
- 3 June 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (9) , 2180-2187
A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
Aims: Early clinical studies have indicated that the pharmacokinetics of Atuliflapon (AZD5718) are time and dose dependent. The reason(s) for these findings is(are) not fully understood, but pre‐clinical profiling suggests that time‐dependent CYP3A4 inhibition cannot be excluded. In clinical practice, Atuliflapon will be co‐administered with CYP3A4 substrates; thus, it is important to determine the impact of Atuliflapon on the pharmacokinetics (PK) of CYP3A4 substrates. The aim of this study was to evaluate the effect of Atuliflapon on the pharmacokinetics of a sensitive CYP3A4 substrate, midazolam, and to explore if the time‐/dose‐dependent effect seen after repeated dosing could be an effect of change in CYP3A4 activity.Methods: Open‐label, fixed‐sequence study in healthy volunteers to assess the PK of midazolam alone and in combination with Atuliflapon. Fourteen healthy male subjects received single oral dose of midazolam 2 mg on days 1 and 7 and single oral doses of Atuliflapon (125 mg) from days 2 to 7. A physiologically based pharmacokinetic (PBPK) model was developed to assess this drug–drug interaction.Results: Mean midazolam values of maximum plasma concentration (Cmax) and area under the curve (AUC) to infinity were increased by 39% and 56%, respectively, when co‐administered with Atuliflapon vs. midazolam alone. The PBPK model predicted a 27% and 44% increase in AUC and a 23% and 35% increase in Cmax of midazolam following its co‐administrations with two predicted therapeutically relevant doses of Atuliflapon.Conclusions: Atuliflapon is a weak inhibitor of CYP3A4; this was confirmed by the validated PBPK model. This weak inhibition is predicted to have a minor PK effect on CYP3A4 metabolized drugs.
- 3 June 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (9) , 2180-2187
Open AccessA drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
Aims: Early clinical studies have indicated that the pharmacokinetics of Atuliflapon (AZD5718) are time and dose dependent. The reason(s) for these findings is(are) not fully understood, but pre‐clinical profiling suggests that time‐dependent CYP3A4 inhibition cannot be excluded. In clinical practice, Atuliflapon will be co‐administered with CYP3A4 substrates; thus, it is important to determine the impact of Atuliflapon on the pharmacokinetics (PK) of CYP3A4 substrates. The aim of this study was to evaluate the effect of Atuliflapon on the pharmacokinetics of a sensitive CYP3A4 substrate, midazolam, and to explore if the time‐/dose‐dependent effect seen after repeated dosing could be an effect of change in CYP3A4 activity.Methods: Open‐label, fixed‐sequence study in healthy volunteers to assess the PK of midazolam alone and in combination with Atuliflapon. Fourteen healthy male subjects received single oral dose of midazolam 2 mg on days 1 and 7 and single oral doses of Atuliflapon (125 mg) from days 2 to 7. A physiologically based pharmacokinetic (PBPK) model was developed to assess this drug–drug interaction.Results: Mean midazolam values of maximum plasma concentration (Cmax) and area under the curve (AUC) to infinity were increased by 39% and 56%, respectively, when co‐administered with Atuliflapon vs. midazolam alone. The PBPK model predicted a 27% and 44% increase in AUC and a 23% and 35% increase in Cmax of midazolam following its co‐administrations with two predicted therapeutically relevant doses of Atuliflapon.Conclusions: Atuliflapon is a weak inhibitor of CYP3A4; this was confirmed by the validated PBPK model. This weak inhibition is predicted to have a minor PK effect on CYP3A4 metabolized drugs.
- Open Access
- 6 March 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (2) , e1184
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses
Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non‐alcoholic steatohepatits and chronic obstructive pulmonary disease. We aimed to assess the risk of QT‐interval prolongation with mitiperstat using concentration–QT (C‐QT) modeling. Healthy male volunteers were randomized to receive single oral doses of mitiperstat 5, 15, 45, 135, or 405 mg (n = 6 per dose) or matching placebo (n = 10) in a phase 1 study (NCT02712372). Time‐matched pharmacokinetic and digital electrocardiogram data were collected at the baseline (pre‐dose) and at 11 time‐points up to 48 h post‐dose. C‐QT analysis was prespecified as an exploratory objective. The prespecified linear mixed effects model used baseline‐adjusted QT interval corrected for the heart rate by Fridericia's formula (ΔQTcF) as a dependent variable and plasma mitiperstat concentration as an independent variable. Initial exploratory analyses indicated that all model assumptions were met (no effect on heart rate; appropriate use of QTcF; no hysteresis; linear concentration–response relationship). Model‐predicted mean baseline‐corrected and placebo‐adjusted ΔΔQTcF was +0.73 ms (90% confidence interval [CI]: −1.73, +3.19) at the highest anticipated clinical exposure (0.093 μmol/L) during treatment with mitiperstat 5 mg once daily. The upper 90% CI was below the established threshold of regulatory concern. The 16‐fold margin to the highest observed exposure was high enough to mean that a positive control was not needed. Mitiperstat is not associated with risk of QT‐interval prolongation at expected therapeutic concentrations.
- 6 March 2024
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 12 (2) , e1184
Open AccessThe myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses
Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non‐alcoholic steatohepatits and chronic obstructive pulmonary disease. We aimed to assess the risk of QT‐interval prolongation with mitiperstat using concentration–QT (C‐QT) modeling. Healthy male volunteers were randomized to receive single oral doses of mitiperstat 5, 15, 45, 135, or 405 mg (n = 6 per dose) or matching placebo (n = 10) in a phase 1 study (NCT02712372). Time‐matched pharmacokinetic and digital electrocardiogram data were collected at the baseline (pre‐dose) and at 11 time‐points up to 48 h post‐dose. C‐QT analysis was prespecified as an exploratory objective. The prespecified linear mixed effects model used baseline‐adjusted QT interval corrected for the heart rate by Fridericia's formula (ΔQTcF) as a dependent variable and plasma mitiperstat concentration as an independent variable. Initial exploratory analyses indicated that all model assumptions were met (no effect on heart rate; appropriate use of QTcF; no hysteresis; linear concentration–response relationship). Model‐predicted mean baseline‐corrected and placebo‐adjusted ΔΔQTcF was +0.73 ms (90% confidence interval [CI]: −1.73, +3.19) at the highest anticipated clinical exposure (0.093 μmol/L) during treatment with mitiperstat 5 mg once daily. The upper 90% CI was below the established threshold of regulatory concern. The 16‐fold margin to the highest observed exposure was high enough to mean that a positive control was not needed. Mitiperstat is not associated with risk of QT‐interval prolongation at expected therapeutic concentrations.